

RECORDATI: PUBLIC DISCLOSURE

Milan, 1 March 2017 – Please be informed that the Directors' Reports relating to the item 1 (profit allocation), item 2 (appointment of the Board of Directors) and item 3 (appointment of the Board of Statutory Auditors) of the agenda of the Ordinary and Extraordinary Shareholders' Meeting called for April 11th 2017, single call, are available to the public, as of today, at the Company's registered office and published on the Company's website (www.recordati.it; Section Investors, Shareholders' Meetings) and on the "1info" storage mechanism (www.1info.it). Further documentation relating to other items of the agenda of the aforementioned Ordinary and Extraordinary Shareholders' Meeting will be published with the same means and terms pursuant to the applicable laws and regulations' provisions.

Please be also informed that, today, the project of cross border merger by absorption in RECORDATI S.p.A. of the Luxembourg company, entirely held, Recordati SA Chemical and Pharmaceutical Company, was filed with the Companies' Register of Milan. Therefore, the shareholders of Recordati S.p.A. that represent at least 5% of the share capital may ask, within eight days as of today, for the decision to be made by means of a shareholders resolution pursuant to article 2502 of Italian Civil Code, as per article 2505, paragraph 3, of the Italian Civil Code.

The documentation relating to the aforementioned transaction - including the common merger project, the Board of Directors management report to the merger, the financial statements as of 31 December 2016 of both merging companies, represented by, respectively, the 2016 Annual Accounts duly approved by the Shareholders meeting of Recordati SA Chemical and Pharmaceutical Company, and the proposed 2016 financial statements as of 31 December 2016 approved on 1st March 2017 by the Board of Directors of Recordati S.p.A. – is available to the public at the Company's registered office and published on the Company's website (www.recordati.it; Section Corporate Governance, Other Corporate Documents) and on the "1info" storage mechanism (www.1info.it).

Moreover, the Annual Accounts of the last three accounting years relating to each merging company are available at each merging company's registered office.

Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of around 4,000, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in the main European countries, in Russia, in other Central and Eastern European countries, in Turkey, in North Africa, in the United States of America and in some Latin American countries. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties within the urogenital therapeutic area and of treatments for rare diseases. Consolidated revenue for 2016 was € 1,153.9 million, operating income was € 327.4 million and net income was € 237.4 million.

For further information:

Recordati website: www.recordati.com

Investor Relations

Marianne Tatschke
(39)0248787393
e-mail: inver@recordati.it

Media Relations

Studio Noris Morano
(39)0276004736, (39)0276004745
e-mail: norismorano@studionorismorano.com

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Sede Legale
VIA M. CIVITALI, 1
20148 MILANO, ITALIA
TEL. (39) 0248787.1
FAX (39) 0240073747

CAPITALE SOCIALE € 26.140.644,50 I.V.
REG. IMP. MILANO N. 00748210150
CODICE FISCALE/P.IVA 007482210150
R.E.A. MILANO N. 401832